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Abstract
Background: The medical use of cannabis has been legislatively restricted for decades in the US and abroad. In
recent years, changing local and national policies have given rise to a community of healthcare providers who may
be recommending the medical use of cannabis without the benefit of formal clinical practice guidelines or
sufficient training and education. In addition, a citizen science movement has emerged whereby unlicensed and
untrained individuals are acting as healthcare provider proxies, offering cannabis-specific clinical care to “patients”.
This study sought to characterize the clinical practice characteristics of these provider groups.
Methods: An anonymous, online survey was designed to describe levels of cannabis-specific education, practice
characteristics, indications for medical use, dose, administration forms and adverse effects related to cannabis use. The
questionnaire was disseminated via professional medical cannabis associations and by word-of-mouth. It was accessed
between June 31–December 31, 2018. A self-selecting sample of respondents (n = 171) completed the survey.
Results: Formal education or training in the medical use of cannabis was significantly more common among licensed
respondents than unlicensed respondents (95.5% vs 76.9% respectively, OR, 6.3, 95% CI, 1.2–32.3, p = 0.03). The vast
majority (n = 74, 83.15%) of licensed respondents reported having recommended cannabis as an adjunct to an existing
prescription drug. Almost two-thirds (n = 64, 71.9%) reported having recommended it as a substitute. When delta-9-
tetrahydrocannabinol (THC) is the principal therapeutic constituent of interest, vaporization is the most common
method of administration recommended (n = 94 responses, 71.4% of respondents). In contrast, when cannabidiol
(CBD) is the principal therapeutic constituent of interest, oral administration (sublingual or oromucosal absorption) is
the most common method (n = 70 responses, 71.4% of respondents).
Conclusions: Individuals who recommend the medical use of cannabis appear to be self-generating a community
standard of practice in the absence of formal clinical guidelines on dosing, interactions and other characteristics.
Reducing barriers to clinical research on cannabis products is needed, not only to better understand their risks and
benefits, but also to augment the evidence-base for informing clinical practice.
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Introduction
Cannabis sativa L. (Cannabis spp. or Cannabis) is used as
both a recreational drug and a botanical medicine. In the
United States, the Drug Enforcement Administration
(DEA) has considered cannabis (i.e., marijuana) a Sched-
ule I controlled substance since the passage of the Con-
trolled Substances Act in 1970 [1]. Despite this status, and
as of this writing, 33 states, the District of Columbia,
Guam and Puerto Rico, have legalized the medical use of
cannabis [2]. In addition, 11 states, and the District of
Columbia, have legalized cannabis for recreational use by
adults, with more states likely to follow [3].
This phenomenon is not confined to the US, however.
Canada and Uruguay have also legalized adult use of
cannabis. In the UK, cannabis products have been
moved to Schedule 2, allowing some products to be pre-
scribed as medicines [4]. Cannabis-derived medicines
have also been authorized by other European countries,
including Italy, Croatia, Netherlands, and the Czech
Republic [5].
In the US, states with regulated medical cannabis pro-
grams allow licensed healthcare providers to qualify pa-
tients pursuant to that state’s eligibility criteria. Many, but
not all, of these providers also manage these patients’
symptoms and medical conditions over time using canna-
bis as a medicine. Decades-long restrictions on clinical tri-
als investigating cannabis have thwarted the evidence base
upon which clinical practice would typically be informed
[6]. As a result, guidance on dosage, methods of adminis-
tration, contraindications, adverse events, prescription
drug interactions, and other important aspects of clinical
care has been lacking [7]. While educational resources are
available, they may be insufficient for providers to feel
confident recommending cannabis as a therapeutic option
[8, 9]. For example, 85% of medical students reported not
receiving education on the topic at medical school or in
residency, and 90% reported not feeling prepared to “pre-
scribe” medical cannabis [9]. In another study, fewer than
20% of Colorado family physicians reported that they had
received any information on medical cannabis in their for-
mal education [10]. Only three states have required any
training or certification in order to qualify patients for
their medical cannabis programs [11].
In the absence of adequately-trained, licensed health-
care providers to advise patients, unlicensed individuals
have stepped into the void to serve as healthcare pro-
vider proxies, promoting and advocating the use of
cannabis as a medicine [12, 13]. In some cases these
unlicensed individuals may be employees of cannabis
dispensaries. In one study, 94% of such individuals re-
ported providing specific dosing advice to customers,
despite their lack of evidence-based training [14].
This scenario has precipitated several potential con-
cerns. Despite good intentions, such individuals may not
recognize when considerable medical risk is present [15].
Also, they may not be oriented toward fundamental ten-
ants of medical ethics, including informed consent regard-
ing treatment options [14, 15]. Further, they may be
industry-funded, and thus operating with an undisclosed
conflict of interest. In some instances, these individuals
are effectively practicing medicine without a license and
may be making recommendations that conflict with delta
9-tetrahydrocannabinol (THC)-oriented safety guidelines
from national organizations, such as the American College
of Obstetricians and Gynecologists (ACOG) regarding the
use of cannabis in pregnancy [15].
The purpose of this study was to examine and describe
a variety of characteristics of both licensed healthcare
providers and these unlicensed healthcare proxies who
are recommending the medical use of cannabis to their
patients or clients. These characteristics span multiple
domains and are detailed below.
Methods
Survey
The authors developed a novel questionnaire with three
distinct aims: 1. To examine and describe the socio-
demographic, education, training and clinical practice
characteristics of licensed healthcare providers and
unlicensed healthcare provider proxies who recommend
the medical use of cannabis; 2. To differentiate and
elucidate their observations, opinions and practices, and
determine whether there is any consensus with regard to
indications, dosing, methods of administration, perceived
effectiveness, prescription drug substitution and differenti-
ation between approaches utilizing THC and Cannabidiol
(CBD) as independent modalities; and 3. To characterize
the anecdotal observations, opinions and practices involving
the tolerability and safety of cannabis products, including
adverse effects, prescription drug interactions, contrain-
dications and cannabis use disorders. The survey was
tested for comprehension and clarity of aims using an
iterative process by which a select group of individuals
completed the questionnaire under supervision by the
authors. The final survey consisted of 255 structured
questions including yes/no, single response, multiple
response and slider/visual analog scale answers.
Respondents were a self-selected convenience sample
who accessed the online survey from June 29, 2018 to
December 31, 2018 at https://www.medicalcannabis.study.
Recruitment strategies included email promotion via sev-
eral organizations which have emerged to address the need
for professional development around the medical use of
cannabis, including the American Cannabis Nurses Associ-
ation (ACNA), the Society of Cannabis Clinicians (SCC),
the American Academy of Cannabinoid Medicine (AACM)
and HelloMD. Other recruitment strategies included invita-
tions sent via email to licensed cannabis dispensaries,
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medical cannabis educational and training programs and a
list-serve of medical cannabis professionals in Canada. The
only participation criterion was answering “Yes” to the fol-
lowing question: “Do you provide services that include
recommending and/or advising and/or educating individ-
uals in the use of cannabis for medical or therapeutic
purposes?”
Study data were collected and managed using the Re-
search Electronic Data Capture (REDCap) [16] platform
hosted at National University of Natural Medicine. RED-
Cap is a secure, web-based application designed to sup-
port data capture for research studies, providing: 1) an
intuitive interface for data entry (minimum and max-
imum values were pre-set); 2) audit trails for tracking
data manipulation and export procedures; 3) automated
export procedures for seamless data downloads to com-
mon statistical packages; and 4) procedures for import-
ing data from external sources.
Documentation of informed consent was secured at
the start of the survey, initially using an electronic signa-
ture and later using a checkbox for affirmation (Y/N) of
having read and agreed to the Informed Consent agree-
ment. The only record linking the respondent with their
responses was an optional field at the end of the survey
where respondents could type their email address in order
to be notified when the data were published in a manu-
script. Procedures were in accordance with the ethical stan-
dards of the Declaration of Helsinki, as revised in 2008.
The institutional review board (IRB) of National University
of Natural Medicine approved the study protocol.
Data analyses
To meet Aims 1–3, descriptive statistics were calculated, in-
cluding frequencies, simple proportions, means and stand-
ard deviations, to describe socio-demographics, clinical
practice characteristics, education and training, perceived
effectiveness, adverse effects, contraindications, dosage and
other attributes. To detect differences between provider
types, bivariate comparisons were conducted using fre-
quency procedures and chi-square or binary logistic regres-
sion where appropriate. Data analyses were conducted using
SAS University Edition (SAS 9.4) (SAS Institute Inc., Cary,
NC). An alpha threshold of alpha = 0.05 was applied for all
unique significance tests. Bonferroni corrections were
applied to pairwise comparisons where relevant. Figures
were produced using GraphPad Prism, Version 6.
Results
Socio-demographic characteristics
A total of 171 respondents completed the survey, includ-
ing fourteen different types of licensed providers (includ-
ing “Other”) and four different types of unlicensed
healthcare provider proxies (including “Other”) (See
Table 1). The overall survey was comprised of
Table 1 Socio-demographic and other characteristics of survey





Decline to State 0 (0)
Missing 6






United States 140 (87.0)
Other 21 (13.0)
Missing 10













Registered Nurse (RN) 66 (46.5)
Medical & Osteopathic Doctor (MD, DO) 39 (27.5)
Other 27 (19.0)
Naturopathic Doctor (ND) 12 (8.5)
Physician’s Assistant & Nurse Practitioner 10 (7.0)
Missing 2
State Regulatory Status
State regulated MMJ** program 133 (87.5)




Does not provide 92 (61.3)
Missing 21
Key: * Does not sum to 144 or 100% because providers can hold more than
one license type. ** MMJ = Medical Marijuana
Corroon et al. BMC Family Practice          (2019) 20:174 Page 3 of 12
respondents from 22U.S. states and 12 foreign countries.
Unlicensed proxies comprised less than 15% of the sample
(n = 25, 14.8% of respondents). The most frequently
reported type of unlicensed individual was “Non-employee
- Cannabis Consultant/Specialist/Educator”. Only three
respondents identified as “Employee - Cannabis retailer”.
Education & Training
The majority of respondents (n = 94, 93.1%) reported
having received at least some formal education or train-
ing in advising or educating patients or clients in how to
use cannabis for medical purposes. Receipt of formal
education or training was more common among li-
censed than unlicensed respondents (95.5% vs 76.9%
respectively, OR, 6.3, 95% CI, 1.2–32.3, p = 0.03), This
finding was not statistically significant after applying
Bonferroni correction, however.
Less than one third (n = 25, 28.4%) of licensed respon-
dents reported receiving specific education about the
endocannabinoid system in their formal medical training,
or specific education in recommending cannabis in clin-
ical situations. Respondents reported participating in both
CME-certified and non-CME-certified education (61.7%
for both). Despite the fact that many respondents (n = 57,
56.4%) reported that the available education was
insufficient, roughly three-quarters (n = 71, 75.5%) felt it
adequately prepared them to advise patients and clients in
the medical use of cannabis, and that the education was
free of conflicts of interest (n = 68, 72.3%). There were no
statistically significant differences between licensed and
unlicensed respondents in relation to conflicts of interest
in available education and training.
Clinical practice characteristics
Almost 60% of respondents (n = 90, 59.2%) reported
recommending and/or advising and/or educating indi-
viduals in the use of cannabis for medical or thera-
peutic purposes for more than 2 years. The number
of “visits” per patient reported by licensed respon-
dents was fairly evenly distributed across the re-
sponses with approximately one quarter reporting 1–2
visits per patient (n = 31, 24.2%) and another quarter
reporting more than 5 visits per patient (n = 33,
25.8%). Roughly a third (n = 43, 33.1%) of licensed re-
spondents offer their services using telemedicine.
Just under half (n = 59, 45.7%) of licensed respon-
dents reported recommending cannabis to a majority
of their patients and clients, while 13.2% (n = 17) re-
ported recommending it in each and every visit. Al-
most three-quarters (n = 110, 73.3%) of all
Fig. 1 Top 5 most frequently selected symptoms/conditions for which respondents perceive effectiveness by phytocannabinoid, ranked by
perceived effectiveness score (in descending order). Respondents were asked, “In your experience, which symptom(s)/condition(s) are most
effectively treated with either CBD or THC-dominant cannabis flower and products? (Check all that apply)”. Bars reflect the mean respondent-
perceived effectiveness score treated with either CBD (white) or THC (grey). Respondents rated each symptom/condition using the following
scale: 0–32 = minimally effective, 33–65 = moderately effective, > 66 = extremely effective. Error bar is the standard deviation of effectiveness
score; mean value reported on the right side of the graph. IBD: inflammatory bowel disease; PTSD: posttraumatic stress disorder
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respondents reported that the majority of their pa-
tients or clients were inexperienced and had never
used cannabis before.
Almost 90% of all licensed respondents (n = 114,
87.7%) reported practicing in a state, or country, that af-
fords their patients legal access to cannabis products. A
minority (n = 58, 38.7%) reported providing written au-
thorizations qualifying patients for a state or country
regulated medical cannabis program (See Table 1).
Methods of administration
Patient and client preference for methods of administra-
tion in decreasing order were: oral (ingestion: n = 78,
69.6% and sublingual or intra-oral: n = 71, 63.4%); topical
or transdermal (n = 65, 58.0%); and inhalation (vaporiz-
ing: n = 59, 52.7% and smoking: n = 44, 39.3%). It is com-
mon for patients and clients to utilize more than one
method of administration.
When THC is the principal therapeutic constituent of
interest, vaporizing was the most frequent method of ad-
ministration reported (n = 94 responses, 71.4% of respon-
dents). In contrast, when CBD is the principal therapeutic
constituent of interest, oral methods of administration
were more frequently reported (sublingual or oromucosal
absorption: n = 70 responses, 71.4% of respondents; inges-
tion: n = 66 responses, 67.3% of respondents).
Clinical effectiveness
Mean provider perceived effectiveness scores for symp-
toms/conditions treated with cannabis are presented in
Fig. 1 below for both CBD-dominant and THC-dominant
flower and products.
The symptoms/conditions with the 10 highest Mean
Effectiveness Scores across both THC-dominant and
CBD-dominant flower and products are presented in
Fig. 2 below in descending order.
Dosing
For inhaled CBD-dominant flower and products, respon-
dents selected “I advise titrating up from a low dose” as
the most frequent dosing response for 18 out of the 25
different symptoms/ conditions (exceptions: anorexia,
asthma, CVD, chronic pain, hypertension, infertility,
stroke). For orally administered CBD, respondents se-
lected this response for 21 out of the 25 (exceptions:
CVD, infertility, anorexia, infertility). For both inhaled
and orally administered THC-dominant flower and
products, respondents selected “I advise titrating up
Fig. 2 Perceived effectiveness of phytocannnabinoids by symptom/condition, ranked by perceived effectiveness score (in descending order).
Respondents were asked, “In your experience, how effective are either CBD or THC-dominant cannabis flower and products at treating [symptom/
condition]?”. Bars reflect the mean respondent-perceived effectiveness score treated with either CBD (white) or THC (grey). Respondents rated
effectiveness for each symptom/condition using the following scale: 0–32 = minimally effective, 33–65 = moderately effective, > 66 = extremely
effective. Error bar is the standard deviation of effectiveness score; mean value reported on the right side of the graph. PTSD: posttraumatic stress
disorder; IBD: inflammatory bowel disease
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from a low dose” as the most frequent dosing response
for 23 out of the 25 different symptoms/conditions (in-
halation exceptions: anorexia, infertility; orally adminis-
tered exceptions: CVD, infertility).
Quantifiable dosing information for the symptoms/
conditions for which THC and CBD-dominant flower
and products were most frequently reported being ef-
fective are highlighted in Fig. 3a for CBD and 3b for
THC. Dosing information is only provided for oral
administration.
The most frequently selected quantifiable dosing re-
sponse for oral administration for treating cancer was
> 120 mg per day (15.1% of respondents) for CBD
and > 50 mg per day (17.5% of respondents) for THC.
Hemp versus marijuana
More than two-thirds (n = 68, 68.7%) reported recom-
mending marijuana-derived CBD products over hemp-
derived CBD products. Almost half (n = 49 respon-
dents, 49.49%) reported that “based on observation and
experience” marijuana-derived CBD products were
more effective. Approximately 30% (n = 29 respon-
dents, 29.3%) reported not knowing which was more
effective. When asked to select the most common
intended effects when recommending CBD, respon-
dents predominantly reported intending to achieve re-
ductions in pain and inflammation (91.9 and 89.9% of
respondents respectively), as well as anxiety (84.8% of
respondents).
Fig. 3 Average daily dose of phytocannabinoids for the top 5 symptoms/conditions (Ingestion). Respondents were asked, “When recommending
either CBD or THC as the principal therapeutic constituent, what daily dose of CBD/THC do you typically recommend for the following
symptom(s)/condition(s) when ingestion is the method of administration?”. Respondents only answered for conditions that they treat and were
not required to record a response for every symptom/condition. Bars reflect the average mg/day dose of either: a) CBD, most commonly used by
respondents for anxiety, arthritis, fibromyalgia, sleep disorders and HA/migraine (Top 5 by frequency); or, b) THC, most commonly used for
chronic pain, fibromyalgia, arthritis, sleep disorders and anorexia (Top 5 by frequency). The percent response for each dose is numbered inside
the bar graph with the standard deviation (CBD, n = 99; THC, n = 132). (% does not =100% as respondents could choose other options such as “I
don’t give quantitative dosing advice”)
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Adverse effects
Respondents were offered 16 unique adverse effect re-
sponses for THC and CBD, plus “Other” (See Appendix
A, 7–8. for list of adverse effects). When asked if pa-
tients or clients reported adverse effects (Y/N) when
using THC and/or CBD-dominant flower and products,
roughly twice as many respondents answered affirmatively
when referring to THC (Yes: 65.5% vs 33.3% respectively).
Respondents also reported a greater frequency of adverse
effects with treatments involving THC as compared
to CBD (n = 386 total adverse effects reported by 72
respondents for THC; n = 74 reported by 31 respon-
dents for CBD).
The most frequently reported adverse effect of CBD-
dominant flower and products (i.e., Fatigue/Sedation,
n = 21 respondents, 67.7% of respondents) was equal in
frequency to the 9th most frequently reported adverse
effect of THC (i.e., Tachycardia, heart palpitations, n = 21
responses, 29.2% of respondents) (See Table 2).
Approximately one-third (n = 31, 33.3%) of respon-
dents reported that their patients or clients experienced
adverse effects from isolated CBD or CBD-dominant
flower or products. Interestingly, the difference in fre-
quency between the most frequently reported adverse ef-
fect of CBD (i.e., Fatigue/Sedation) and the second most
frequently reported adverse effect of was substantial (i.e.,
Headache) (n = 21, 67.7% vs n = 7, 22.6%, respectively).
The most frequently reported “Other” adverse effect was
diarrhea (n = 3).
Contraindications
Respondents were asked about absolute contraindica-
tions for recommending THC and CBD-dominant
flower and products. Respondents were offered 10
unique absolute contraindication responses, plus “I don’t
know”, “No” and “Other” (See Appendix A, 9 for list of
contraindications.).
Three hundred thirty-four responses for absolute
contraindications were recorded for THC-dominant
flower and products by 110 different respondents, while
191 were recorded for CBD-dominant flower and prod-
ucts by 93 different respondents (See Fig. 4 below).
This represents 3.0 absolute contraindications per re-
spondent for THC-dominant flower and products as
compared to 2.1 for CBD-dominant flower and prod-
ucts. The most commonly reported “Other” contraindi-
cation for CBD was concurrent use with anti-coagulant
therapy.
Over half of respondents (n = 49, 55.7%) reported
that “there are clinically significant interactions (phar-
macokinetic/dynamic) between cannabis and certain
prescription drugs”.
Adjunctive therapy & prescription drug substitution
The vast majority (n = 74, 83.15%) of licensed respon-
dents reported having recommended cannabis as an ad-
junctive therapy to an existing prescription drug.
Figure 5 below summarizes the most frequently re-
ported classes/categories of drugs to which cannabis
was added. The three most frequently reported out-
comes when adding cannabis as an adjunctive therapy
were: “Improvement of symptoms” (n = 63 responses,
85.1%); “Decrease in dose of prescription medication”
(n = 55, 74.3%); and “Discontinuation of prescription
medication” (n = 37, 50.0%).
Almost three-fourths (n = 64, 71.9%) of licensed re-
spondents reported having recommended cannabis as
a substitute for an existing prescription drug. Figure 5
also summarizes the most frequent classes/categories
of drugs for which cannabis was recommended as a
substitute. When asked if the substitution was sus-
tained, 64.1% of licensed respondents reported “Yes”
(n = 41, 64.1%). Almost 30% reported “Not sure/Lost
Table 2 Top 10 adverse effects – THC (n = 72 respondents) & CBD (n = 31 respondents)
THC CBD
Rank Adverse effect % of Respondents Adverse effect % of Respondents
1 Fatigue, sedation 65.3 Fatigue, sedation 67.7
2 Anxiety 63.9 Other 45.2
3 Dry mouth and eyes 54.2 Headache 22.6
4 Dizziness 52.8 Anxiety 16.1
5 Appetite stimulation 37.5 Dizziness 12.9
6 Impaired concentration 36.1 Dry mouth and eyes 12.9
7 Dysphoria 34.7 Impaired concentration 12.9
8 Impaired memory 31.9 Nausea, vomiting 12.9
9 Tachycardia, heart palpitations 29.2 Tachycardia, heart palpitations 9.7
10 Altered sense of time 26.4 Appetite stimulation 6.5
*This is a multiple response variable (i.e., Check all that apply). Percent of respondents, not responses. Does not sum to 100%
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Fig. 4 Top 5 absolute contraindications for recommending THC or CBD. Respondents were asked, “Are any of the following absolute
contraindications for recommending CBD/THC-only or CBD/THC-dominant cannabis products (Check all that apply)?” The bars indicate the % of
respondents who selected each contraindication. The percentage is labeled at the end of each bar (THC, n = 110; CBD, n = 93)
Fig. 5 Percent reporting that patients/clients use cannabis as an adjunctive or drug substitution therapy. Respondents were asked, “If you have
ever recommended cannabis as a complementary therapy to [substitute for] a prescription drug, what class/category of drug(s) did you intend to
complement [substitute] with cannabis (Check all that apply)?” Bars reflect the % of respondents who selected each class/category. The
percentage is labeled at the end of each bar. The gray bar indicates respondents reporting using cannabis as a substitute (n = 64). The black bar
indicates respondents reporting using cannabis as an adjunct (n = 74)
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to follow-up” (n = 19 respondents, 29.7%) and 6.3%
reported “No” (n = 4, 6.25%).
Cannabis use disorders
Licensed respondents were asked, “Have any of your
patients and clients ever developed a use disorder
involving cannabis as defined by the Diagnostic and
Statistical Manual of Mental Disorders, 5th Edi-
tion?”. Almost 90% (n = 78, 88.6%) reported observ-
ing cannabis withdrawal syndrome, while less than
6% (n = 5, 5.7%) reported observing cannabis use
disorder.
Discussion
To our knowledge, this is the first survey to report com-
munity, practice-based observations, opinions and prac-
tices of healthcare providers and unlicensed healthcare
proxies who are actively advising patients or clients in
the medical use of cannabis. These results suggest that
there is consensus among these individuals regarding
the need for more and higher quality education, and a
lack of consensus regarding dosing of phtyocannabinoids
and contraindications for medical use. These data may
not be generalizable to practitioners across the globe,
however. The sample was largely comprised of Cauca-
sian females in their mid-50s years of age who provide
these services in states with regulated medical cannabis
programs. Licensed Registered Nurses were the single
largest provider type, although more than 25% were
Medical Doctors. Unlicensed healthcare proxies com-
prised less than 15% of the sample.
Despite generally high rates of participation in formal
education and training, the present observations indicate
that available education may be insufficient, consistent
with previous reports [8, 9]. This insufficiency, combined
with the lack of prospective clinical research, may be
creating a wide disparity in observations, opinions and
practices among providers, who have been passively
forced to create a community standard of practice in the
presence of limited evidence and in absentia of substan-
tive formal practice guidelines.
Respondents indicate that approximately 73% of their
patients and clients report being naïve to cannabis.
These individuals are presumably in need of medical ad-
vice, which would be optimally delivered by individuals
possessing sufficient training, education, and legal au-
thority. Forty-five percent report recommending canna-
bis to a majority of their patients or clients, but only a
small portion (13%) recommend cannabis at every visit.
These data support our observations that when States le-
gislate the medical use of cannabis, providers may seek
to capitalize by forming a medical cannabis specialty
practice. This is very different from Great Britain, for ex-
ample, where doctors are only authorized to prescribe
cannabis products within their own specialty, and only
when other established options for treatment have been
exhausted [15, 17]. Individuals naïve to cannabis may be
seeking expert advice more often than non-naïve users.
Further, the ongoing stigma from the medical commu-
nity at large may drive such individuals to unlicensed
healthcare provider proxies for advice.
In this study, reports of preferences for oral methods
of administration for CBD-dominant products, and in-
halation methods for THC-dominant products, approxi-
mate reports of cannabis users themselves [18, 19].
Administration methods are particularly important with
cannabis because phytocannabinoid pharmacokinetics
are greatly influenced by route of administration. For ex-
ample, compared to inhalation, enteral methods are
marked by low bioavailability of phytocannabinoids, due to
poor aqueous solubility and extensive metabolism [20, 21].
Also, adverse effects occurring as a direct result of the
method of administration (e.g., respiratory irritation via in-
halation) need to be taken into account.
The perceived effectiveness of CBD for chronic pain,
anxiety and sleep disorders, and THC for pain, sleep dis-
orders and anorexia, is corroborated by cross-sectional
studies of cannabis users [18, 19, 22]. However, this study
is the first to describe common dosing parameters cur-
rently being utilized in cannabis-centric clinical practice,
both for oral and inhaled methods of administration. For
many symptoms/conditions, respondents most often rec-
ommended between 16 and 45mg of CBD per day orally,
and between 6 and 10mg of THC per day orally, except
for chronic pain where the reported dose of THC was typ-
ically higher (i.e., 11–30mg). Recommending higher milli-
gram doses of THC for chronic pain, as compared to
most other symptoms/conditions, is consistent with at
least one randomized controlled trial of an oral cannabis
preparation (i.e., Nabiximols) where participants with se-
vere, cancer-related pain titrated up to approximately 30
mg of THC and CBD each daily [23].
Chronic pain was the most frequently selected indi-
cation for using CBD. This observation is consistent
with a cross-sectional study of cannabis users in one
study [22], but interesting given the limited pre-
clinical and clinical evidence supporting the analgesic
effects of CBD [24–27]. More research into the anal-
gesic effects of CBD is needed, including efficacious
dosing and a determination of the types of pain for
which CBD may be effective.
The present observations illustrate how clear and ef-
fective dosing information for individual phytocannabi-
noids is both relatively scarce and yet very important.
These data suggest that there is no clear consensus on
specific dosages for specific conditions, but that the
range of doses utilized in clinical practice is not exces-
sive. Also, it is not unrealistic to speculate that dosing
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may be driven by the products available in the geo-
graphic area of practice.
Methods of estimating the dose of phytocannabinoids
from inhaled cannabis are extremely limited. While the
bioavailability is much greater than orally administered
products [28], milligram amounts of THC and/or CBD
are typically not available on labels of inhaled products.
In addition, meaningful amounts of these compounds
may be lost during combustion (i.e., smoking), or in
“side stream smoke” or vapor [29].
The greater frequency of adverse effects associated with
THC, as compared to CBD, is expected given its intoxicat-
ing potential, and the rates of adverse effects observed in
clinical trials [30]. Despite favorable reports of the safety
and tolerability of CBD [31], it is not without adverse effects
[32]. A high percentage of respondents (67.7%) reported
“Fatigue/Sedation” as an adverse effect. Not surprisingly,
“Fatigue/Sedation” is often the most commonly reported
adverse effect in clinical trials investigating isolated CBD
preparations [33–35]. These analyses did not attempt to as-
sociate adverse effects with dose, despite the fact that ad-
verse effects are known to be dose dependent [7, 23].
To our knowledge, this is the first survey to report
community opinions that marijuana-derived CBD
products may be more clinically effective than hemp-
derived CBD products. This contention is common-
place among industry stakeholders invested in
marijuana-derived CBD products, yet unsubstantiated
by existing scientific studies. It should be noted that
the methodological constraints of the present study
limit its ability to effectively substantiate this claim.
Differences in effects between marijuana-derived and
hemp-derived products may be due to levels of THC,
which can be significantly lower in hemp-derived
products [36].
Use of THC and CBD while pregnant or breastfeeding
was the most commonly reported absolute contraindica-
tion. This community practice is congruent with guide-
lines from the ACOG, the American Academy of
Pediatrics (AAP) and the Centers for Disease Control
and Prevention (CDC) [37–39]. Interestingly, almost half
of respondents do not consider THC to be contraindi-
cated during pregnancy and while breast feeding, and
therefore may either not be aware of the ACOG/AAP/
CDC guidelines or are choosing not to follow them.
This study supports observations from previous stud-
ies, showing that healthcare providers are recommend-
ing the use cannabis as both an adjunctive and
substitute therapy for a variety of prescription medica-
tions, most commonly opioid and non-opioid analgesics,
anti-depressants and anxiolytics [18, 40, 41]. The per-
spective of those surveyed here is that the addition and/
or substitution of cannabis is allowing individuals to re-
duce symptoms, decrease the dose, and/or discontinue
use of prescription medications. Some medications to
which cannabis is being added to, or substituted for,
have a narrow therapeutic window or are prone to inter-
actions. This area should be an urgent research priority.
Strengths & Limitations
This study has several strengths, including: a multi-state re-
cruitment approach; dissemination via representative orga-
nizations, as well as, through grassroots word-of-mouth
increasing generalizability; inclusion of, and discrimination
between, both licensed and unlicensed respondents; differ-
entiation between methods of administration, dose and
form (flower or processed product) of cannabis-derived
products.
Nevertheless, the study has several limitations. The popu-
lation was a self-selected convenience sample, and as such,
may not be representative of the general population. At the
time of writing the questionnaire, we estimated 1000
healthcare providers. A sample size of 95 would provide
95% confidence in detecting a 20-point difference between
proportions powered at 80%. The sample size estimate was
based on an approximation of the membership of the pro-
fessional organizations that were engaged to assist with re-
cruitment, as well as an estimate of the size of the authors
collective professional networks thru which the question-
naire was distributed. An estimate of licensed dispensaries
in San Diego, CA and Portland, Oregon was also incorpo-
rated. Also, providers with favorable opinions of, or experi-
ences with, cannabis may be more likely to have responded.
When uncoupled, observations herein are more likely at-
tributable to licensed respondents, as opposed to
unlicensed respondents, due to the predominance of re-
spondents in that group. Since the survey was primarily cir-
culated via the internet, providers with limited technology
access may be underrepresented. Beyond the solicitation of
provider opinions on clinical efficacy, the survey did not
attempt to discriminate between hemp-derived and
marijuana-derived products, which may have differing
chemical constituents, particularly with regard to THC, and
therefore different therapeutic and/or adverse effects. Nor
did they survey attempt to inquire observations, opinions
or practices related to terpenes/terpenoids, which are also
known to have biological activity [42]. No mechanism for
identifying repeat respondents was incorporated into the
survey. Although results were examined manually, it is pos-
sible (albeit unlikely because there was no incentive to do
so) that repeat respondents may have distorted the results.
Finally, due to a technical glitch, data on dosing was not
captured for oral dosing of CBD for chronic pain and inhal-
ation dosing of THC for sleep disorders.
Conclusion
Collectively, the results reported here indicate that li-
censed healthcare providers and unlicensed healthcare
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provider proxies are recommending the medical use of
cannabis to their patients or clients, independent of state
regulations and licensure, and despite insufficient educa-
tion and training. These individuals are seeking out
training that was not provided in their formal education
and generally report safe and effective health outcomes.
Among these outcomes include symptom reduction and
a decreased reliance on prescription medications. A self-
generating community standard of practice may be
emerging in the absence of formal clinical guidelines.
Reducing barriers to formal clinical research on cannabis
products is needed, not only to better understand their
risks and benefits, but also to augment the evidence-
base for informing clinical practice.
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